MET and hepatocellular carcinoma: Comparing mouse HCC models to their human counterparts led to the discovery that activating mutations of β-catenin co-occur with activation of the Met protein-tyrosine kinase, pinpointing a previously unappreciated cooperation between Wnt and Met signaling in HCC [17].